Lung Cancer
Conditions
Interventions
Opioid Group :intravenous injection of sufentanil
opioid-free and opioid-spare Group:A multimodal analgesic strategie: intercostal nerve block, a visual laryngoscope for spraying in topicalisation, intravenous injection of esketamine and lidocaine.
Sponsors
Suzhou Dushu Lake Hospital(Dushu Lake Hospital Affiliated to Soochow University)
Eligibility
Sex/Gender
All
Age
18 Years to 8 Years
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following inclusion criteria to be enrolled: 1)Age =18 years old, no gender limit; 2) The American Society of Anesthesiologists anesthesia risk score is level I-III; 3) The anesthetist in charge believes that the patient is eligible for inclusion; 4) Clearly understand, voluntarily participate in the study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will not be enrolled in this study: 1) Patients with heart conduction system block; 2) Patients with Adams-Strokes syndrome; 3) Patients taking beta-blockers for a long time and whose heart rate is lower than 50 beats/minute; 4) History of epileptic seizures; 5) Heart failure; unstable angina; 6) Patients who are judged to have difficulty in respiratory tract management (modified Mahalanobis level IV); 7) Those suffering from severe respiratory diseases (obstructive sleep apnea syndrome, mouth opening disorder, limited neck or jaw movement, morbid obesity, acute respiratory infection, acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, etc.) For patients, SPO2<95% when inhaling air before surgery; 8) Hemoglobin <90g/L; 9) Abnormal liver function, alanine aminotransferase and/or aspartate aminotransferase = 2.5 times the upper limit, total bilirubin = 1.5 times the upper limit; 10) Abnormal renal function, serum creatinine =1.5 times the upper limit; 11) Emergency surgery; 12) Women who are pregnant or breastfeeding; 13) Those who are allergic to or have contraindications to the drugs and drug components used during surgical anesthesia; 14) The researcher considers it inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD3+: total T lymphocytes;CD3+CD4+: Th cells;CD3+CD8+: Ts cells;Th/Ts cell ratio;CD19+: B lymphocytes;CD16+CD56+: NK cells;Average length of stay after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| postoperative pain;Postoperative analgesic drug consumption;Respiratory depression;feel sick and vomit;Intestinal defecation and flatulence;Incidence of serious complications within 30 days after surgery (cardiocerebrovascular events, respiratory failure, secondary surgery, readmission, death); | — |
Countries
China
Contacts
Public ContactLi Jian
Suzhou Dushu Lake Hospital(Dushu Lake Hospital Affiliated to Soochow University)
Outcome results
None listed